Xtant Medical (XTNT) Expected to Announce Quarterly Earnings on Monday

Xtant Medical (NYSEAMERICAN:XTNT - Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results after the market closes on Monday, May 12th. Analysts expect Xtant Medical to post earnings of ($0.02) per share and revenue of $30.65 million for the quarter.

Xtant Medical Stock Performance

Shares of Xtant Medical stock traded down $0.03 during trading on Friday, hitting $0.50. 56,793 shares of the stock were exchanged, compared to its average volume of 94,000. Xtant Medical has a 1-year low of $0.33 and a 1-year high of $0.85. The stock has a market capitalization of $70.16 million, a price-to-earnings ratio of -3.88 and a beta of 0.35. The company has a fifty day moving average price of $0.47 and a 200-day moving average price of $0.50. The company has a current ratio of 2.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.42.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.